TABLE 1.
ISCL/EORTC Staging
| Stage | TNMB Classification | Median OS (years) | 10-year(6) | |||||
|---|---|---|---|---|---|---|---|---|
| T | N | M | B | OS (%) | DSS (%) | RDP (%) | ||
| IA | 1 | 0 | 0 | 0,1 | 35.5 | 88 | 95 | 12 |
|
| ||||||||
| IB | 2 | 0 | 0 | 0,1 | 21.5 | 70 | 77 | 38 |
|
| ||||||||
| IIA | 1, 2 | 1 | 0 | 0,1 | 15.8 | 52 | 67 | 33 |
|
| ||||||||
| IIB | 3 | 0–2 | 0 | 0,1 | 4.7 | 34 | 42 | 58 |
|
| ||||||||
| IIIA | 4 | 0–2 | 0 | 0 | 4.7 | 37 | 45 | 62 |
|
| ||||||||
| IIIB | 4 | 0–2 | 0 | 1 | 3.4 | 25 | 45 | 73 |
|
| ||||||||
| IVA1 | 1–4 | 0–2 | 0 | 2 | 3.8 | 18 | 20 | 83 |
|
| ||||||||
| IVA2 | 1–4 | 3 | 0 | 0–2 | 2.1 | 15 | 20 | 80 |
|
| ||||||||
| IVB | 1–4 | 0–3 | 1 | 0–2 | 1.4 | 18 (5 year) | 18 (5 year) | 82 (5 year) |
OS, overall survival; DSS, disease-specific survival; RDP, risk of disease progression